Friday, 20 July 2018 - 7:54
  • it
  • de
  • en
  • fr

Exondys 51

Anthem decides not to cover costs for Sarepta’s Exondys 51

One of the main U.S. insurers, Anthem, has announced it will not cover Sarepta’s newly FDA approved Exondys 51 (eteplirsen), for the treatment of Duchenne muscular dystrophy. Anthem is the first insurance company to make such a decision, while, for…

BioMarin-Sarepta litigation still ongoing

After FDA approved Exondys 51 in DMD, BioMarin Pharmaceutical stated it intends to revise the decision by the U.S. Patent Trial and Appeal Board (PTAB), which decided in favor of Sarepta Therapeutics. This is a step forward escalating the litigation…

Sarepta defines price for Exondys 51

After being granted the FDA approval on Monday for Exondys 51 , the first drug to treat patients with Duchenne muscular dystrophy, Sarepta has defined the drug price, that is about $300,000 annually per patient. Exondys 51 will be available…

Sarepta’s eteplirsen, first muscular dystrophy drug, has been approved

FDA approved today Sarepta’s Exondys 51 (eteplirsen) injection. This is the first drug approved to treat patients with Duchenne muscular dystrophy (DMD). It is particularly indicated for patients with a specific mutation, which affects 13% of the population with DMD….